CoChat

New Insights into the Role of IL-1β in Experimental Autoimmune Encephalomyelitis and Multiple Sclerosis

Open access
Lin, Chih-Chung, Edelson, Brian T · 2017 · The Journal of Immunology
Cited by 157

The DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.

Abstract

Multiple sclerosis (MS), and its animal model experimental autoimmune encephalomyelitis, are neuroinflammatory diseases driven by autoreactive pathogenic TH cells that elicit demyelination and axonal damage. How TH cells acquire pathogenicity and communicate with myeloid cells and cells of the CNS remain unclear. IL-1β is recognized to play an important role in experimental autoimmune encephalomyelitis (EAE) and perhaps MS. Clinical EAE is significantly attenuated in IL-1R–deficient and IL-1β–deficient mice, and IL-1β is found in the blood, cerebrospinal fluid, and CNS lesions of MS patients. In this article, we focus on new reports that elucidate the cellular sources of IL-1β and its actions during EAE, in both lymphoid tissues and within the CNS. Several immune cell types serve as critical producers of IL-1β during EAE, with this cytokine inducing response in both hematopoietic and nonhematopoietic cells. These findings from the EAE model should inspire efforts toward investigating the therapeutic potential of IL-1 blockade in MS.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.4049/jimmunol.1700263

Cites

16 of 16 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 16 references

Research works printed but not linked: 100

  1. Malik, 2016, The emerging roles of gamma-delta T cells in tissue inflammation in experimental autoimmune encephalomyelitis, Front. Immunol., 7, 14, 10.3389/fimmu.2016.00014 · DOI · Paper page
  2. Salou, 2015, Involvement of CD8(+) T cells in multiple sclerosis, Front. Immunol., 6, 604, 10.3389/fimmu.2015.00604 · DOI · Paper page
  3. Sinha, 2015, CD8(+) T-cells as immune regulators of multiple sclerosis, Front. Immunol., 6, 619, 10.3389/fimmu.2015.00619 · DOI · Paper page
  4. Hohlfeld, 2016, The search for the target antigens of multiple sclerosis, part 2: CD8+ T cells, B cells, and antibodies in the focus of reverse-translational research, Lancet Neurol., 15, 317, 10.1016/S1474-4422(15)00313-0 · DOI · Paper page
  5. Claes, 2015, B cells are multifunctional players in multiple sclerosis pathogenesis: insights from therapeutic interventions, Front. Immunol., 6, 642, 10.3389/fimmu.2015.00642 · DOI · Paper page
  6. Stromnes, 2006, Active induction of experimental allergic encephalomyelitis, Nat. Protoc., 1, 1810, 10.1038/nprot.2006.285 · DOI · Paper page
  7. Levine, 1973, Experimental allergic encephalomyelitis in inbred and outbred mice, J. Immunol., 110, 139, 10.4049/jimmunol.110.1.139 · DOI · Paper page
  8. Bettelli, 1998, IL-10 is critical in the regulation of autoimmune encephalomyelitis as demonstrated by studies of IL-10- and IL-4-deficient and transgenic mice, J. Immunol., 161, 3299, 10.4049/jimmunol.161.7.3299 · DOI · Paper page
  9. Codarri, 2013, Communication between pathogenic T cells and myeloid cells in neuroinflammatory disease, Trends Immunol., 34, 114, 10.1016/j.it.2012.09.007 · DOI
  10. Croxford, 2015, GM-CSF in neuroinflammation: licensing myeloid cells for tissue damage, Trends Immunol., 36, 651, 10.1016/j.it.2015.08.004 · DOI
  11. Becher, 2016, GM-CSF: from growth factor to central mediator of tissue inflammation, Immunity, 45, 963, 10.1016/j.immuni.2016.10.026 · DOI · Paper page
  12. Cerretti, 1992, Molecular cloning of the interleukin-1 beta converting enzyme, Science, 256, 97, 10.1126/science.1373520 · DOI · Paper page
  13. Thornberry, 1992, A novel heterodimeric cysteine protease is required for interleukin-1 beta processing in monocytes, Nature, 356, 768, 10.1038/356768a0 · DOI · Paper page
  14. Piccioli, 2013, The secretion of IL-1β and options for release, Semin. Immunol., 25, 425, 10.1016/j.smim.2013.10.007 · DOI
  15. Boraschi, 2013, The interleukin-1 receptor family, Semin. Immunol., 25, 394, 10.1016/j.smim.2013.10.023 · DOI · Paper page
  16. Symons, 1987, Cerebrospinal fluid interleukin 1 like activity during chronic relapsing experimental allergic encephalomyelitis, Clin. Exp. Immunol., 68, 648
  17. Mannie, 1987, Interleukin 1 and myelin basic protein synergistically augment adoptive transfer activity of lymphocytes mediating experimental autoimmune encephalomyelitis in Lewis rats, J. Immunol., 138, 4229, 10.4049/jimmunol.138.12.4229 · doi:10.4049/jimmunol.138.12.4229
  18. Baker, 1991, Cytokines in the central nervous system of mice during chronic relapsing experimental allergic encephalomyelitis, Cell. Immunol., 134, 505, 10.1016/0008-8749(91)90321-2 · DOI
  19. Kennedy, 1992, Analysis of cytokine mRNA expression in the central nervous system of mice with experimental autoimmune encephalomyelitis reveals that IL-10 mRNA expression correlates with recovery, J. Immunol., 149, 2496, 10.4049/jimmunol.149.7.2496 · DOI · Paper page
  20. Bauer, 1993, Demonstration of interleukin-1 beta in Lewis rat brain during experimental allergic encephalomyelitis by immunocytochemistry at the light and ultrastructural level, J. Neuroimmunol., 48, 13, 10.1016/0165-5728(93)90053-2 · DOI
  21. Jacobs, 1991, Experimental autoimmune encephalomyelitis is exacerbated by IL-1 alpha and suppressed by soluble IL-1 receptor, J. Immunol., 146, 2983, 10.4049/jimmunol.146.9.2983 · DOI · Paper page
  22. Martin, 1995, Protective effect of the interleukin-1 receptor antagonist (IL-1ra) on experimental allergic encephalomyelitis in rats, J. Neuroimmunol., 61, 241, 10.1016/0165-5728(95)00108-E · DOI
  23. Badovinac, 1998, Interleukin-1 receptor antagonist suppresses experimental autoimmune encephalomyelitis (EAE) in rats by influencing the activation and proliferation of encephalitogenic cells, J. Neuroimmunol., 85, 87, 10.1016/S0165-5728(98)00020-4 · DOI
  24. Wiemann, 1998, Combined treatment of acute EAE in Lewis rats with TNF-binding protein and interleukin-1 receptor antagonist, Exp. Neurol., 149, 455, 10.1006/exnr.1997.6723 · DOI
  25. Schiffenbauer, 2000, The induction of EAE is only partially dependent on TNF receptor signaling but requires the IL-1 type I receptor, Clin. Immunol., 95, 117, 10.1006/clim.2000.4851 · DOI
  26. Sutton, 2006, A crucial role for interleukin (IL)-1 in the induction of IL-17-producing T cells that mediate autoimmune encephalomyelitis, J. Exp. Med., 203, 1685, 10.1084/jem.20060285 · DOI · Paper page
  27. Lukens, 2012, Inflammasome-derived IL-1β regulates the production of GM-CSF by CD4(+) T cells and γδ T cells, J. Immunol., 188, 3107, 10.4049/jimmunol.1103308 · DOI · Paper page
  28. Lin, 2016, IL-1-induced Bhlhe40 identifies pathogenic T helper cells in a model of autoimmune neuroinflammation, J. Exp. Med., 213, 251, 10.1084/jem.20150568 · DOI · Paper page
  29. Lévesque, 2016, Myeloid cell transmigration across the CNS vasculature triggers IL-1β-driven neuroinflammation during autoimmune encephalomyelitis in mice, J. Exp. Med., 213, 929, 10.1084/jem.20151437 · DOI · Paper page
  30. Mufazalov, 2017, IL-1 signaling is critical for expansion but not generation of autoreactive GM-CSF+ Th17 cells, EMBO J., 36, 102, 10.15252/embj.201694615 · DOI
  31. Matsuki, 2006, Abnormal T cell activation caused by the imbalance of the IL-1/IL-1R antagonist system is responsible for the development of experimental autoimmune encephalomyelitis, Int. Immunol., 18, 399, 10.1093/intimm/dxh379 · DOI · Paper page
  32. Inoue, 2012, NLRP3 inflammasome induces chemotactic immune cell migration to the CNS in experimental autoimmune encephalomyelitis, Proc. Natl. Acad. Sci. USA, 109, 10480, 10.1073/pnas.1201836109 · DOI · Paper page
  33. Inoue, 2012, Interferon-β therapy against EAE is effective only when development of the disease depends on the NLRP3 inflammasome, Sci. Signal., 5, ra38, 10.1126/scisignal.2002767 · DOI · Paper page
  34. Inoue, 2016, An interferon-β-resistant and NLRP3 inflammasome-independent subtype of EAE with neuronal damage, Nat. Neurosci., 19, 1599, 10.1038/nn.4421 · DOI · Paper page
  35. Shaw, 2010, Cutting edge: critical role for PYCARD/ASC in the development of experimental autoimmune encephalomyelitis, J. Immunol., 184, 4610, 10.4049/jimmunol.1000217 · DOI · Paper page
  36. Furlan, 1999, Caspase-1 regulates the inflammatory process leading to autoimmune demyelination, J. Immunol., 163, 2403, 10.4049/jimmunol.163.5.2403 · DOI · Paper page
  37. Hisahara, 2001, Caspase-11 mediates oligodendrocyte cell death and pathogenesis of autoimmune-mediated demyelination, J. Exp. Med., 193, 111, 10.1084/jem.193.1.111 · DOI
  38. Shao, 2014, Activating cannabinoid receptor 2 alleviates pathogenesis of experimental autoimmune encephalomyelitis via activation of autophagy and inhibiting NLRP3 inflammasome, CNS Neurosci. Ther., 20, 1021, 10.1111/cns.12349 · DOI · Paper page
  39. Lalor, 2011, Caspase-1-processed cytokines IL-1beta and IL-18 promote IL-17 production by gammadelta and CD4 T cells that mediate autoimmunity, J. Immunol., 186, 5738, 10.4049/jimmunol.1003597 · DOI · Paper page
  40. Hauser, 1990, Cytokine accumulations in CSF of multiple sclerosis patients: frequent detection of interleukin-1 and tumor necrosis factor but not interleukin-6, Neurology, 40, 1735, 10.1212/WNL.40.11.1735 · DOI · Paper page
  41. Dujmovic, 2009, The analysis of IL-1 beta and its naturally occurring inhibitors in multiple sclerosis: the elevation of IL-1 receptor antagonist and IL-1 receptor type II after steroid therapy, J. Neuroimmunol., 207, 101, 10.1016/j.jneuroim.2008.11.004 · DOI
  42. Wucherpfennig, 1992, T cell receptor V alpha-V beta repertoire and cytokine gene expression in active multiple sclerosis lesions, J. Exp. Med., 175, 993, 10.1084/jem.175.4.993 · DOI · Paper page
  43. Woodroofe, 1993, Cytokine mRNA expression in inflammatory multiple sclerosis lesions: detection by non-radioactive in situ hybridization, Cytokine, 5, 583, 10.1016/S1043-4666(05)80008-0 · DOI · Paper page
  44. Cannella, 1995, The adhesion molecule and cytokine profile of multiple sclerosis lesions, Ann. Neurol., 37, 424, 10.1002/ana.410370404 · DOI · Paper page
  45. Argaw, 2006, IL-1beta regulates blood-brain barrier permeability via reactivation of the hypoxia-angiogenesis program, J. Immunol., 177, 5574, 10.4049/jimmunol.177.8.5574 · DOI · Paper page
  46. Burm, 2016, Expression of IL-1β in rhesus EAE and MS lesions is mainly induced in the CNS itself, J. Neuroinflammation, 13, 138, 10.1186/s12974-016-0605-8 · DOI
  47. Seppi, 2014, Cerebrospinal fluid IL-1β correlates with cortical pathology load in multiple sclerosis at clinical onset, J. Neuroimmunol., 270, 56, 10.1016/j.jneuroim.2014.02.014 · DOI
  48. Rossi, 2014, Cerebrospinal fluid detection of interleukin-1β in phase of remission predicts disease progression in multiple sclerosis, J. Neuroinflammation, 11, 32, 10.1186/1742-2094-11-32 · DOI
  49. Furlan, 1999, Peripheral levels of caspase-1 mRNA correlate with disease activity in patients with multiple sclerosis; a preliminary study, J. Neurol. Neurosurg. Psychiatry, 67, 785, 10.1136/jnnp.67.6.785 · DOI · Paper page
  50. Heidary, 2014, The analysis of correlation between IL-1B gene expression and genotyping in multiple sclerosis patients, J. Neurol. Sci., 343, 41, 10.1016/j.jns.2014.05.013 · DOI
  51. Peelen, 2015, Increased inflammasome related gene expression profile in PBMC may facilitate T helper 17 cell induction in multiple sclerosis, Mol. Immunol., 63, 521, 10.1016/j.molimm.2014.10.008 · DOI
  52. Ko, 2014, GM-CSF-responsive monocyte-derived dendritic cells are pivotal in Th17 pathogenesis, J. Immunol., 192, 2202, 10.4049/jimmunol.1302040 · DOI · Paper page
  53. Dumas, 2014, The inflammasome pyrin contributes to pertussis toxin-induced IL-1β synthesis, neutrophil intravascular crawling and autoimmune encephalomyelitis, PLoS Pathog., 10, e1004150, 10.1371/journal.ppat.1004150 · DOI · Paper page
  54. Gao, 2016, Blockade of CD47 ameliorates autoimmune inflammation in CNS by suppressing IL-1-triggered infiltration of pathogenic Th17 cells, J. Autoimmun., 69, 74, 10.1016/j.jaut.2016.03.002 · DOI
  55. Secor, 2000, Mast cells are essential for early onset and severe disease in a murine model of multiple sclerosis, J. Exp. Med., 191, 813, 10.1084/jem.191.5.813 · DOI · Paper page
  56. Sayed, 2010, Meningeal mast cells affect early T cell central nervous system infiltration and blood-brain barrier integrity through TNF: a role for neutrophil recruitment?, J. Immunol., 184, 6891, 10.4049/jimmunol.1000126 · DOI · Paper page
  57. Christy, 2013, Mast cell activation and neutrophil recruitment promotes early and robust inflammation in the meninges in EAE, J. Autoimmun., 42, 50, 10.1016/j.jaut.2012.11.003 · DOI · Paper page
  58. Russi, 2016, Meningeal mast cell-T cell crosstalk regulates T cell encephalitogenicity, J. Autoimmun., 73, 100, 10.1016/j.jaut.2016.06.015 · DOI · Paper page
  59. Russi, 2016, Mast cell inflammasome activity in the meninges regulates EAE disease severity, 10.1016/j.clim.2016.04.009 · DOI
  60. Suurmond, 2016, Expansion of Th17 cells by human mast cells is driven by inflammasome-independent IL-1β, J. Immunol., 197, 4473, 10.4049/jimmunol.1502640 · DOI
  61. McCandless, 2009, IL-1R signaling within the central nervous system regulates CXCL12 expression at the blood-brain barrier and disease severity during experimental autoimmune encephalomyelitis, J. Immunol., 183, 613, 10.4049/jimmunol.0802258 · DOI · Paper page
  62. Mandolesi, 2013, Interleukin-1β alters glutamate transmission at purkinje cell synapses in a mouse model of multiple sclerosis, J. Neurosci., 33, 12105, 10.1523/JNEUROSCI.5369-12.2013 · DOI · Paper page
  63. Murphy, 2010, Infiltration of Th1 and Th17 cells and activation of microglia in the CNS during the course of experimental autoimmune encephalomyelitis, Brain Behav. Immun., 24, 641, 10.1016/j.bbi.2010.01.014 · DOI · Paper page
  64. Martin, 2016, T cell-intrinsic ASC critically promotes T(H)17-mediated experimental autoimmune encephalomyelitis, Nat. Immunol., 17, 583, 10.1038/ni.3389 · DOI · Paper page
  65. Guo, 2009, IL-1 family members and STAT activators induce cytokine production by Th2, Th17, and Th1 cells, Proc. Natl. Acad. Sci. USA, 106, 13463, 10.1073/pnas.0906988106 · DOI · Paper page
  66. Chung, 2009, Critical regulation of early Th17 cell differentiation by interleukin-1 signaling, Immunity, 30, 576, 10.1016/j.immuni.2009.02.007 · DOI · Paper page
  67. Martínez-Llordella, 2013, CD28-inducible transcription factor DEC1 is required for efficient autoreactive CD4+ T cell response, J. Exp. Med., 210, 1603, 10.1084/jem.20122387 · DOI · Paper page
  68. Lin, 2014, Bhlhe40 controls cytokine production by T cells and is essential for pathogenicity in autoimmune neuroinflammation, Nat. Commun., 5, 3551, 10.1038/ncomms4551 · DOI · Paper page
  69. Fukaya, 2014, Loss of Sprouty4 in T cells ameliorates experimental autoimmune encephalomyelitis in mice by negatively regulating IL-1β receptor expression, Biochem. Biophys. Res. Commun., 447, 471, 10.1016/j.bbrc.2014.04.012 · DOI
  70. Ichiyama, 2016, The microRNA-183-96-182 cluster promotes T helper 17 cell pathogenicity by negatively regulating transcription factor Foxo1 expression, Immunity, 44, 1284, 10.1016/j.immuni.2016.05.015 · DOI · Paper page
  71. Robson, 2016, Generation and characterization of mice expressing a conditional allele of the interleukin-1 receptor type 1, PLoS One, 11, e0150068, 10.1371/journal.pone.0150068 · DOI
  72. Abdulaal, 2016, Characterization of a conditional interleukin-1 receptor 1 mouse mutant using the Cre/LoxP system, Eur. J. Immunol., 46, 912, 10.1002/eji.201546075 · DOI
  73. Mufazalov, 2016, Generation of a novel T cell specific interleukin-1 receptor type 1 conditional knock out mouse reveals intrinsic defects in survival, expansion and cytokine production of CD4 T cells, PLoS One, 11, e0161505, 10.1371/journal.pone.0161505 · DOI
  74. Rothhammer, 2015, Control of autoimmune CNS inflammation by astrocytes, Semin. Immunopathol., 37, 625, 10.1007/s00281-015-0515-3 · DOI · Paper page
  75. Liu, 2015, Interleukin 1 type 1 receptor restore: a genetic mouse model for studying interleukin 1 receptor-mediated effects in specific cell types, J. Neurosci., 35, 2860, 10.1523/JNEUROSCI.3199-14.2015 · DOI · Paper page
  76. Paré, 2017, Involvement of the IL-1 system in experimental autoimmune encephalomyelitis and multiple sclerosis: breaking the vicious cycle between IL-1beta and GM-CSF, Brain Behav. Immun., 62, 1, 10.1016/j.bbi.2016.07.146 · DOI
  77. Aubé, 2014, Neutrophils mediate blood-spinal cord barrier disruption in demyelinating neuroinflammatory diseases, J. Immunol., 193, 2438, 10.4049/jimmunol.1400401 · DOI · Paper page
  78. Li, 2011, Endothelial IL-1R1 is a critical mediator of EAE pathogenesis, Brain Behav. Immun., 25, 160, 10.1016/j.bbi.2010.09.009 · DOI · Paper page
  79. Shirakawa, 1987, Expression of interleukin 1 receptors on human peripheral T cells, J. Immunol., 138, 4243, 10.4049/jimmunol.138.12.4243 · doi:10.4049/jimmunol.138.12.4243
  80. Lee, 2010, Regulating human Th17 cells via differential expression of IL-1 receptor, Blood, 115, 530, 10.1182/blood-2009-08-236521 · DOI · Paper page
  81. Sha, 2016, Activated IL-1RI signaling pathway induces Th17 cell differentiation via interferon regulatory factor 4 signaling in patients with relapsing-remitting multiple sclerosis, Front. Immunol., 7, 543, 10.3389/fimmu.2016.00543 · DOI
  82. Duhen, 2014, IL-1β promotes the differentiation of polyfunctional human CCR6+CXCR3+ Th1/17 cells that are specific for pathogenic and commensal microbes, J. Immunol., 193, 120, 10.4049/jimmunol.1302734 · DOI · Paper page
  83. Calderon, 2006, A role for CXCL12 (SDF-1alpha) in the pathogenesis of multiple sclerosis: regulation of CXCL12 expression in astrocytes by soluble myelin basic protein, J. Neuroimmunol., 177, 27, 10.1016/j.jneuroim.2006.05.003 · DOI · Paper page
  84. Mayo, 2014, Regulation of astrocyte activation by glycolipids drives chronic CNS inflammation, Nat. Med., 20, 1147, 10.1038/nm.3681 · DOI · Paper page
  85. Nicoletti, 1996, Circulating serum levels of IL-1ra in patients with relapsing remitting multiple sclerosis are normal during remission phases but significantly increased either during exacerbations or in response to IFN-beta treatment, Cytokine, 8, 395, 10.1006/cyto.1996.0054 · DOI
  86. Perini, 2000, Interleukin-1 receptor antagonist, soluble tumor necrosis factor-alpha receptor type I and II, and soluble E-selectin serum levels in multiple sclerosis patients receiving weekly intramuscular injections of interferon-beta1a, Eur. Cytokine Netw., 11, 81
  87. Comabella, 2008, Induction of serum soluble tumor necrosis factor receptor II (sTNF-RII) and interleukin-1 receptor antagonist (IL-1ra) by interferon beta-1b in patients with progressive multiple sclerosis, J. Neurol., 255, 1136, 10.1007/s00415-008-0855-1 · doi:10.1007/s00415-008-0855-1
  88. Coclet-Ninin, 1997, Interferon-beta not only inhibits interleukin-1beta and tumor necrosis factor-alpha but stimulates interleukin-1 receptor antagonist production in human peripheral blood mononuclear cells, Eur. Cytokine Netw., 8, 345
  89. Jungo, 2001, IFN-beta inhibits the ability of T lymphocytes to induce TNF-alpha and IL-1beta production in monocytes upon direct cell-cell contact, Cytokine, 14, 272, 10.1006/cyto.2001.0884 · DOI
  90. Guarda, 2011, Type I interferon inhibits interleukin-1 production and inflammasome activation, Immunity, 34, 213, 10.1016/j.immuni.2011.02.006 · DOI · Paper page
  91. Burger, 2009, Glatiramer acetate increases IL-1 receptor antagonist but decreases T cell-induced IL-1beta in human monocytes and multiple sclerosis, Proc. Natl. Acad. Sci. USA, 106, 4355, 10.1073/pnas.0812183106 · DOI · Paper page
  92. Caragnano, 2012, Monocytes P2X7 purinergic receptor is modulated by glatiramer acetate in multiple sclerosis, J. Neuroimmunol., 245, 93, 10.1016/j.jneuroim.2012.02.002 · DOI
  93. Carpintero, 2010, Glatiramer acetate triggers PI3Kδ/Akt and MEK/ERK pathways to induce IL-1 receptor antagonist in human monocytes, Proc. Natl. Acad. Sci. USA, 107, 17692, 10.1073/pnas.1009443107 · DOI
  94. Carpintero, 2011, IFN-β and glatiramer acetate trigger different signaling pathways to regulate the IL-1 system in multiple sclerosis, Commun. Integr. Biol., 4, 112, 10.4161/cib.14205 · doi:10.4161/cib.14205
  95. Mellergård, 2010, Natalizumab treatment in multiple sclerosis: marked decline of chemokines and cytokines in cerebrospinal fluid, Mult. Scler., 16, 208, 10.1177/1352458509355068 · DOI · Paper page
  96. Mellergård, 2012, Association between change in normal appearing white matter metabolites and intrathecal inflammation in natalizumab-treated multiple sclerosis, PLoS One, 7, e44739, 10.1371/journal.pone.0044739 · DOI
  97. Furlan, 2007, HSV-1-mediated IL-1 receptor antagonist gene therapy ameliorates MOG(35-55)-induced experimental autoimmune encephalomyelitis in C57BL/6 mice, Gene Ther., 14, 93, 10.1038/sj.gt.3302805 · DOI
  98. Warabi, 2007, Role of IL-1 and potential therapies in multiple sclerosis, Drug Discov. Today, 4, 19
  99. Dinarello, 2012, Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases, Nat. Rev. Drug Discov., 11, 633, 10.1038/nrd3800 · DOI · Paper page
  100. Schett, 2016, Interleukin-1 function and role in rheumatic disease, Nat. Rev. Rheumatol., 12, 14, 10.1038/nrrheum.2016.166 · DOI · Paper page

Cited by

Metadata

Authors
Lin, C.-C., & Edelson, B. T.
Venue
The Journal of Immunology
Published
2017-06
Volume
198
Issue
12
Pages
4553-4560
ISSN
  • 0022-1767 (ISSN-L)
  • 1550-6606
OpenAlex
W2624289631
Cited by
157
References
16
FWCI
9.46
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.